PATLY.AIApplication
17401600 · Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
Filed 2021-08-13 · Abandoned The official file ↗ · Art unit 1623 · Examiner Layla D Berry Typical · CPC A61K 31/506 · Novartis AG · NOVARTIS PHARMACEUTICAL CORPORATION
Office actions
1
first was Non-final rejection
RCEs
0
no appeal
To first action
17.7 mo
to disposition 29.2 mo
Statutes raised
103 112
1 actions read